Luke Coutinho on weight loss for Indians: ‘Food is no longer a choice, it's medicine'

Nutritional science expert and best-selling author Luke Coutinho insists that food has to be treated as medicine. 'And they have to be as natural as possible,' he says. That's how he has helped many lose weight, reverse their blood pressure, cholesterol and fatty liver, manage their sugar and even fight cancer. Just by going back to the basics.
'Given the disease burden in our country, food is unfortunately not a choice anymore. We have to understand how food works on the gut microbes, on immune and stem cells, even DNA. It is all about understanding how nutrients react with molecules. Nutrition is now a key pillar of preventive health,' he says.
Excerpts:
Nothing is a magic pill. What most people do not want to understand is that novel weight loss pills like Mounjaro work on one fundamental principle — reducing your appetite. In other words, this is based on denial and suppression, a drastic step intended to help you get off the weight loss plateau, a stage when the body fat gets too stubborn to be lost through the diet-exercise routine and exposes you to a high risk of type 2 diabetes, heart disease, sleep apnea and certain types of cancer. These pills can help you lose up to 22.5% of your body weight over 72 weeks. Then you have to continue the medication and still maintain the weight drop with lifestyle changes. If people don't learn how to change their behaviour around food and lifestyle before the pill or while taking the pill, then they may regain body weight.
At the same time, it doesn't work for everyone. Many people get fantastic results, some experience minimal effects. So it's not a 100 per cent guarantee of weight loss. Mounjaro is an absolute lifesaver when it's given to the population that it was actually meant for, like people who weigh over 120 kg. Question is if it is psychologically motivating enough for them too to make lifestyle changes that matter subsequently. They must take care of their muscle mass with strength training exercises. They must firm up their gut health, change their protein and fibre intake, balance out their macronutrient pie and look out for vitamin and mineral deficiencies.
That you can use it to knock off five to ten kilos because you are too lazy to make lifestyle changes and then get back to your life as if it's a disease you cure. Stopping weight loss drugs means your hunger returns that much stronger. The reward centres in the brain still want you to consume, the drugs are just hiding this desire. A medicine is a medicine. It's not something that we fool around with. We should take it with the right intention, the right guidance and with the mindset that we still need to change our lifestyle.
Is the 70-30 (70 per cent diet and 30 per cent exercise) formula the ideal way to lose weight?
It's easier to control calorie intake than to burn a large number of calories through exercise alone. So diet is indeed a key pillar of any weight loss strategy.
Your gut is everything. It controls how food is broken down into energy, amino acids and fatty acids and is then absorbed into the body. It controls your mind, anxiety and neurotransmitters. It regulates almost 75 per cent of your immune system and hormonal balance. A healthy gut can burn up food for energy, making it easier to lose weight. If not, unused calories get absorbed, affecting hormones that regulate appetite and trigger inflammation.
There are millions and millions of strains of bacteria, fungi and micro-organisms in the gut. But probiotic supplements pick up one strain of lactobacillus as your immunity shield. It's like looking at only one sapling in the Amazon forest. The gut microbiome is a forest where both good and bad bacteria live in balance. But if we feed the bad bacteria through our lifestyle, junk food and sugar, then the good bacteria can't do their job and get outnumbered. What we call gut cleanse or gut reset is really about starving the bad bacteria to death by going off sugar completely for two weeks. The cravings vanish, you start to lose weight, you feel lighter and your gut starts to get better.
We were never supposed to suppress hunger, which is a protective mechanism of the human body. The body makes us hungry because at that point it's looking for certain vitamins, minerals and macro nutrients like carbs, proteins and fats. Unfortunately, we feed it the wrong thing and the body becomes hungrier for what it wants. When you have mostly refined carbs, the body's need for protein or good fat is not met and your burger bun is no substitute. Never ever try to follow diets which advocate suppressing hunger. Instead, eat a nutrient-dense meal which gives you the bulk needed for satiety like whole grains, legumes, fruits, vegetables, lean proteins and nuts.
The second reason we do not experience satiety even while eating the right food is because we are eating to feed our emotions. We eat when we are angry, sad, stressed or bored, seeking relief in food. Eat mindfully, not mindlessly.
Sugar, salt and fat. These trigger the pleasure centres of the brain and release 'feel-good' chemicals such as dopamine and serotonin, affecting the same area of the brain as drugs and alcohol. Even restaurants play with these three ingredients. That's why you keep ordering a particular dish. That's how food companies work.
People eat their last meal at 10 pm and sleep by 11 pm. You need three hours to digest food, which will be unused and become extra calories.
Only influencers say fruits are making you fat. I can guarantee that no human being can ever become fat because they eat fruits unless they're diabetic and have a fatty liver that cannot absorb fructose. Other than that, you can eat fruits and not put on weight because they have no fat and are rich in fibre.
Ghee is often mistaken as a saturated fat but there are good saturated fats and bad saturated fats. The bad saturated fats are your bakery products, junk and processed food. Good saturated fats can help you with heart disease, brain health, even cancers. These include pure ghee, cold pressed mustard oils or wood churned oils. Ghee is rich in Omega 3, and used in moderation, has great uses. Our most common foods like amla, the strongest source of vitamin C, guavas, moringa, ginger, turmeric and other spices are grossly under-rated.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Mint

7 hours ago

• Mint

How weight-loss drugs blew out the US trade deficit

Planes have been jetting from Ireland to the U.S. this year carrying something more valuable than gold: $36 billion worth of hormones for popular obesity and diabetes drugs. The frantic airlift of those ingredients—more than double what was imported from Ireland for all of last year—reflects the collision of two powerful forces: tariff-driven stockpiling and weight-loss drug demand. The peptide and protein-based hormones feed into a category of drugs that include wildly popular GLP-1 treatments and newer types of insulin known as analogues. Taken together the shipments weighed just 23,400 pounds, according to U.S. trade data, equivalent to the weight of less than four Tesla Cybertrucks. Fit into temperature-controlled air cargo containers, the pharmaceutical ingredients have had a huge impact on the U.S. trade imbalance. The shipments have vaulted Ireland, a country of only 5.4 million people, into the second-largest goods-trade imbalance with the U.S., trailing only China. They accounted for roughly half of the $71 billion in goods the U.S. imported from the country in the first four months of the year. Nearly 100% of the imports had a final destination of Indiana, according to U.S. customs records. Eli Lilly, the drug giant behind weight loss and diabetes drugs Zepbound and Mounjaro, is headquartered in Indianapolis. A Lilly spokeswoman declined to comment. President Trump's off-and-on trade war has rewritten global trading patterns this year and—temporarily, at least—widened some of the imbalances he is seeking to eliminate. Companies have scrambled to get shipments to the U.S. ahead of tariff deadlines, with a first round of front-loading ahead of the April 2 announcement, and smaller pushes after the White House paused some of its tariffs. Ireland is at the epicenter of the global rush. It is a major hub for U.S. drug giants, who have been expanding operations there in part because of Ireland's favorable tax policies. Some of the bestselling drugs in the world, such as AbbVie's anti-wrinkle treatment Botox, and U.S. drugmaker Merck's cancer treatment Keytruda, are made in the country. 'It's common sense. It's uncertain at the moment, so you're building a bit of security by stockpiling," said Matt Moran, a consultant and former director of industry group BioPharmaChem Ireland. 'There's such huge demand for those products at the moment." The trade imbalance has put Ireland into an uncomfortable position, landing it earlier this month on the U.S. Treasury Department's monitoring list for currency manipulation, which the government uses to send a warning shot to countries it thinks use unfair trade practices. Ireland's central bank said in a report Thursday that new factories making weight-loss drug ingredients helped drive the country's exports. Ireland's first-quarter economic growth expanded by nearly 10% in the first quarter thanks to the export surge. The attention is 'definitely not welcome," said Dan O'Brien, chief economist of the Institute of International and European Affairs, a Dublin think tank. 'A very big part of the U.S.-EU deficit is accounted for by Ireland alone. Trump doesn't like deficits." The White House wants American drug companies to bring production home and in April ordered a so-called Section 232 investigation that could result in tariffs on both imported drugs and ingredients like hormones. Trump said this week that such tariffs could come 'very soon." Lilly is a force in the market for weight-loss drugs, with sales of its GLP-1 medicines Mounjaro and Zepbound expected to nearly double this year to about $30 billion, according to Bank of America analysts. Maintaining supply of weight-loss drugs has been a challenge for both Lilly and rival Novo Nordisk, the Danish maker of Ozempic and Wegovy. The companies were initially unable to keep up with demand for the drugs. Lilly resolved the shortages faster, helping it to take market share from Novo. Lilly is now preparing for the potential launch of a weight-loss pill, orforglipron, which it plans to submit for U.S. approval later this year. Lilly said it began producing weight-loss and diabetes medicines at its Irish factory in Kinsale in 2023. Novo doesn't produce weight-loss drugs in Ireland, according to a spokeswoman. Peptide and protein-based hormones help to regulate processes such as appetite and metabolism. The category includes hormones that mimic a naturally occurring gut hormone called glucagon-like peptide-1, or GLP-1, but can also be used in some fertility and osteoporosis treatments. Shipping and logistics companies say they have noticed increased demand for pharma shipments, which often travel by air instead of on cheaper ocean freighters because they are so light and valuable. Pharma shipments more than doubled from Ireland to the U.S. in March and April, according to data firm WorldACD. Kuehne + Nagel, a Swiss logistics company with operations in the country, said its teams did overtime to accommodate the increase in booking requests and the customs paperwork. 'We didn't see the same increase from Ireland to the rest of the world. That was not a global trend," said Nico Sacco, the company's senior vice president of healthcare strategy. Imports of vaccines and various other drugs including cancer treatments also increased this year from Ireland, according to trade data. Merck produces cancer treatment Keytruda, the world's bestselling drug, in Ireland, among other places. Merck Chief Executive Rob Davis in April said the company has enough supply to mitigate any impact this year from tariffs and is working on navigating the long-term fallout of tariffs. Merck recently began construction on its first U.S. plant to make Keytruda. Lilly said earlier this year it plans to invest $27 billion in expanding U.S. production. The hormones are often freeze dried and shipped as powders. Obesity-related drugs can fly in the cargo sections of passenger planes, or on cargo flights reserved for pharma products, said Anand Kulkarni, head of global markets at Lufthansa Cargo. Lufthansa saw demand for U.S.-bound pharma shipments from locations such as India, Switzerland and Belgium. Volumes began to dip in April as warehouses in the U.S. reached capacity, he said. To increase shipments, drug companies likely tapped existing stocks and diverted production destined for the rest of the world to the U.S. market instead, industry executives said. 'You can't just switch on capacity. You don't go out and buy machines and start them up," said Moran, the consultant. 'They have to be built, commissioned, validated, and approved by the regulator." Write to Chelsey Dulaney at and Jared S. Hopkins at

Business Standard

9 hours ago

• Business Standard

India's response to obesity drug Mounjaro 'positive', says Eli Lilly

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The US-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May, according to data from research firm PharmaTrac. With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the US. "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24 per cent of women and nearly 23 per cent of men aged 15 to 49 were overweight or obese, up from 20.6 per cent and 19 per cent, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Time of India

11 hours ago

• Time of India

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May, according to data from research firm PharmaTrac. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: 1 simple trick to get all TV channels Techno Mag Learn More Undo With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the U.S. Live Events "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24% of women and nearly 23% of men aged 15 to 49 were overweight or obese, up from 20.6% and 19%, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India.